APTT Reagent Phospholipid Composition for Lupus Anticoagulant Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current APTT reagents have varying sensitivity to lupus anticoagulant (LA) and heparin, leading to inappropriate coagulation time measurements for normal and abnormal blood samples, which complicates screening tests for intrinsic coagulation factors and heparin therapy monitoring.
Innovation Solution
An APTT reagent with a specific phospholipid composition, including phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), with a PS/PC ratio of 0.16 to 0.25 and PS concentration of 7 to 13 µg/mL, is developed to improve sensitivity to LA while maintaining appropriate sensitivity to heparin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If APTT reagents with low phospholipid concentration are used to improve sensitivity to LA, then sensitivity to LA is improved, but coagulation time for normal blood samples becomes prolonged
Solution Approach 1:
The patent applies parameter changes by precisely controlling the phospholipid composition parameters - specifically setting PS concentration at 25 µg/ml or more and establishing a PS/PC ratio between 0.10 and 0.30. This optimized parameter range resolves the contradiction by maintaining sufficient phospholipid concentration to prevent prolonged coagulation times in normal samples while achieving improved sensitivity to LA through the specific PS/PC ratio configuration.
Solution Approach 2:
The patent uses composite materials by combining three types of phospholipids (PS, PC, and PE) in specific proportions rather than using a single phospholipid type. This composite approach allows the reagent to achieve both high sensitivity to LA and appropriate coagulation times for normal samples, as the different phospholipids work synergistically to balance the competing requirements.
2Measurement precision
If APTT reagents with high sensitivity to LA are used, then detection of abnormal samples is improved, but sensitivity to heparin becomes inappropriate
Solution Approach 1:
The patent resolves this contradiction by optimizing the phospholipid composition parameters - specifically setting PS concentration at 25 µg/ml or more and PS/PC ratio between 0.10 and 0.30. This parameter optimization achieves high sensitivity to LA while simultaneously maintaining appropriate sensitivity to heparin, allowing the same reagent to be used for both LA screening and heparin monitoring without compromising either measurement accuracy.
3Measurement precision
If APTT reagents with varying phospholipid composition are used, then sensitivity to LA varies, but this complicates screening tests for intrinsic coagulation factors
Solution Approach 1:
The patent resolves this issue by establishing specific parameter ranges for phospholipid composition - PS concentration of 25 µg/ml or more and PS/PC ratio of 0.10 to 0.30. Within these optimized parameters, the reagent achieves high sensitivity to LA while maintaining normal coagulation times for normal samples, making it suitable for both LA screening and intrinsic coagulation factor screening without requiring different reagents for different test types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reagent provides improved sensitivity to LA, allowing for accurate detection of abnormal samples while maintaining normal coagulation times for healthy samples and appropriate sensitivity to heparin, enhancing the reliability of coagulation tests.
Implementation Method 1
activators and phospholipids are used for the activation of intrinsic coagulation factors and the promotion of blood coagulation
Implementation Method 2
LA inhibits the phospholipid required for blood coagulation, whereby the APTT becomes prolonged for LA-containing blood samples
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Disclosed is a reagent for determination of activated partial thromboplastin time, comprising: a phosphatidylcholine (PC); a phosphatidylserine (PS); and a phosphatidylethanolamine (PE), wherein a concentration ratio of the PS relative to the PC is not less than 0.16 and not more than 0.25, and a concentration of the PS is not less than 7 µg/mL and not more than 13 µg/mL.